GI Transit
Natural health product licensed in Canada
- Other names
- Cyto GI Transit, Cyto-Transit, GI Motility, GI Transit Matrix, GIT-1, Pro-Biotik, Pro-Biotik Bowel Transit, Probiotic Motility, Probiotic Transit
- Licence holder
- Cyto-Matrix Inc.
- NPN or DIN-HM
- 80101315
- Status
- Active licence
- Licence date
- 3 June 2020
- Revision date
- 2 March 2022
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Bifidobacterium animalis subsp. lactis Source : Cellule entière | 1.8 Milliards d'UFC | Not calculated |
| Bifidobacterium animalis subsp. lactis Source : HN019 | 1.8 Milliards d'UFC | Not calculated |
Non-medicinal ingredients
Sucrose, Stéarate de magnésium, Hypromellose, Phosphate de potassium monobasique, acacia, Phosphate de dipotassium, Vitamine C
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
Source of probiotics. Helps support intestinal/gastrointestinal health. Could promote favourable gut flora. Promotes favourable gut flora/intestinal microflora. Reduces whole gut transit time/helps to accelerate intestinal transit time. Supports digestion by reducing transit time. Reduces frequency of functional gastrointestinal symptoms (e.g. constipation, irregularity, flatulence). Promotes bowel movement. Helps provide gentle relief of constipation and/or irregularity.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
If you have fever, vomiting, bloody diarrhoea or severe abdominal pain, consult a health care practitioner prior to use. If symptoms of digestive upset (e.g. diarrhea) occur, worsen, or persist beyond 3 days, discontinue use and consult a health care practitioner. If you have an immune-compromised condition (e.g. AIDS, lymphoma, patients undergoing long-term corticosteroid treatment), do not use this product.
Source
Official Health Canada record, licence 80101315
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2022. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.